Search
News and events
Published on 04.11.24
New insights into TIL-Based Therapies and advances in cancer immunotherapy
Tumor-infiltrating lymphocytes (TILs) are a critical component of the immune system's response to cancer. These immune cells, which naturally infiltrate tumors, have shown great promise in adoptive cell therapy (ACT).
Tumor-infiltrating lymphocytes (TILs) are a critical component of the immune system's response to cancer. These immune cells, which naturally infiltrate tumors, have shown great promise in adoptive cell therapy (ACT).
Published on 28.10.24
Remotely controlled CAR-T cells: a safer and more flexible approach to cancer immunotherapy
A recent study published in Proceedings of the National Academy of Sciences (PNAS) introduces a new all-in-one ON/OFF-switch chimeric antigen receptor (CAR) design enabling the remote control of T cell activity with two clinically approved drugs, offering a safer and more flexible cancer immunotherapy approach.
A recent study published in Proceedings of the National Academy of Sciences (PNAS) introduces a new all-in-one ON/OFF-switch chimeric antigen receptor (CAR) design enabling the remote control of T cell activity with two clinically approved drugs, offering a safer and more flexible cancer immunotherapy approach.
Published on 24.10.24
Prof. Johanna Joyce joins ADAPTMET: shaping the future of metastasis research
The ADAPTMET consortium, spearheaded by IRB Barcelona, is a collaborative effort involving 14 prominent institutions across Europe, including leading academic, clinical, and industrial organizations committed to cancer and metastasis research.
The ADAPTMET consortium, spearheaded by IRB Barcelona, is a collaborative effort involving 14 prominent institutions across Europe, including leading academic, clinical, and industrial organizations committed to cancer and metastasis research.
Published on 23.10.24
Grant announcement: investigating the impact of aging on cancer immunotherapy
We are pleased to announce that Vannini Lab has been awarded funding by the Swiss National Science Foundation (SNSF) for its research project titled «Mitochondrial reprogramming to restore age-driven metabolic dysfunction and boost Immunotherapy»
We are pleased to announce that Vannini Lab has been awarded funding by the Swiss National Science Foundation (SNSF) for its research project titled «Mitochondrial reprogramming to restore age-driven metabolic dysfunction and boost Immunotherapy»
Published on 23.10.24
Appel d'offre "Soutien aux projets en cryo-microscopie électronique"...
Afin de soutenir des projets innovants faisant appel à la cryo-microscopie électronique et à encourager la formation des jeunes chercheur·euse·s à ces technologies, le décanat de la FBM met au concours des financements spécifiques.
Afin de soutenir des projets innovants faisant appel à la cryo-microscopie électronique et à encourager la formation des jeunes chercheur·euse·s à ces technologies, le décanat de la FBM met au concours des financements spécifiques.
Published on 23.10.24
George Coukos élu membre de l'Académie Nationale de Médecine Américaine
La NAM a annoncé l’élection de 90 membres réguliers et 10 membres internationaux, reconnaissant ceux qui ont fait preuve de réalisations exceptionnelles dans les domaines de la santé et de la médecine. George Coukos, reconnu pour ses découvertes pionnières dans l'immunothérapie des cancers, rejoint ce cercle prestigieux.
La NAM a annoncé l’élection de 90 membres réguliers et 10 membres internationaux, reconnaissant ceux qui ont fait preuve de réalisations exceptionnelles dans les domaines de la santé et de la médecine. George Coukos, reconnu pour ses découvertes pionnières dans l'immunothérapie des cancers, rejoint ce cercle prestigieux.
Published on 22.10.24
Le SIB inaugure un nouveau Centre de bioinformatique des pathogènes
Le SIB Swiss Institute of Bioinformatics a lancé un nouveau Centre de bioinformatique des pathogènes, en s’appuyant sur ses contributions lors de la pandémie COVID-19.
Le SIB Swiss Institute of Bioinformatics a lancé un nouveau Centre de bioinformatique des pathogènes, en s’appuyant sur ses contributions lors de la pandémie COVID-19.
Published on 14.10.24
Subsides de recherche financés par le FNS: nouvelles et nouveaux récipiendaires UNIL-CHUV-Unisa...
Parmi les nouveaux subsides de recherche financés par le FNS, 31 projets de la FBM (UNIL-CHUV-Unisanté) ont été retenus.
Parmi les nouveaux subsides de recherche financés par le FNS, 31 projets de la FBM (UNIL-CHUV-Unisanté) ont été retenus.
Published on 11.10.24
NeoDisc: a cutting-edge tool for neoantigen discovery in personalized cancer immunotherapy
A newly published study in Nature Biotechnology introduces NeoDisc, an innovative computational pipeline that combines genomics, transcriptomics, and mass spectrometry-based immunopeptidomics. NeoDisc provides an advanced solution for identifying and prioritizing tumor-specific antigens, enabling the design of personalized cancer vaccines and improving immunotherapy outcomes.
A newly published study in Nature Biotechnology introduces NeoDisc, an innovative computational pipeline that combines genomics, transcriptomics, and mass spectrometry-based immunopeptidomics. NeoDisc provides an advanced solution for identifying and prioritizing tumor-specific antigens, enabling the design of personalized cancer vaccines and improving immunotherapy outcomes.
